Patent · US Active

Very low-dosed solid oral dosage forms for HRT

US8906890B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Bayer Intellectual Property GmbH · DE

Inventors

Stephan Mletzko · Berlin, DE
Rolf Schürmann · Teltow, DE
Kerstin Gude · Birkenwerder, DE

Key dates

Filing date	Apr 15, 2011
Grant date	Dec 9, 2014
Priority date	—
Expiry date	Oct 22, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.